STRO-001

Follicular Lymphoma Pipeline Shows Promise with Over 55 Therapies in Development

6 months ago

• The follicular lymphoma treatment landscape is evolving, with over 55 therapies in development by more than 50 active pharmaceutical companies. • Key players like Incyte, AstraZeneca, and Johnson & Johnson are evaluating novel drugs, including CAR-T therapies and targeted agents, to improve patient outcomes. • Tafasitamab is expected to have a supplemental Biologics License Application filed in August 2024 for patients who have failed prior therapies. • Emerging therapies in the pipeline include TQ-B3525, NKTR-255, and Zilovertamab vedotin, targeting various mechanisms to combat follicular lymphoma.

Sutro Biopharma and Merck Advance Novel Cytokine Derivative into Phase 1 for Solid Tumors

3 years ago

• Sutro Biopharma announces the dosing of the first patient in a Phase 1 study for a novel cytokine derivative therapeutic developed in collaboration with Merck. • The therapeutic is designed for the treatment of advanced or metastatic solid tumors, marking a significant step in the collaboration between the two companies. • Sutro Biopharma will receive a $10 million payment from Merck as a result of achieving this clinical milestone, per the 2018 agreement. • The collaboration leverages Sutro's XpressCF® and Xpress CF+® platforms for cytokine derivative development, with Merck holding exclusive worldwide rights to resulting therapeutic candidates.

STRO-001 Shows Promise in Relapsed/Refractory B-Cell NHL

4 years ago

• STRO-001, a novel CD74-targeting antibody-drug conjugate (ADC), demonstrates preliminary anti-tumor activity in heavily pre-treated B-cell non-Hodgkin's lymphoma (NHL) patients. • The Phase 1 study of STRO-001 shows it is well-tolerated, with mostly grade 1 or 2 treatment-emergent adverse events and no observed ocular or neuropathy toxicity. • A complete response was observed in a DLBCL patient at the 0.075 mg/kg dose, and partial responses were seen in DLBCL patients at 0.65 mg/kg and 1.27 mg/kg. • The dose escalation study is ongoing, with plans to enroll patients at higher dose levels of STRO-001 to further evaluate safety and efficacy.

Follicular Lymphoma Pipeline Shows Promise with Over 55 Therapies in Development

Sutro Biopharma and Merck Advance Novel Cytokine Derivative into Phase 1 for Solid Tumors

STRO-001 Shows Promise in Relapsed/Refractory B-Cell NHL

Drug Development Updates